the 2012 ACR Guidelines for the Management of Gout that add-on therapy to partially responsive xanthine oxidase inhibitor (XOI) treatment can result in improved SU control When to consider changing ULT strategy Switching to a second XOI over adding a uricosuric agent is conditionally recommended for patients taking their first XOI, who have persistently high SU concentrations (>6 mg/dl) despite maximum-tolerated or FDA-indicated XOI dose, and who have continued frequent gout flares (>2